Maxcyte inc (MXCT) - News Archive

Revolutionizing Cellular Therapy: MaxCyte and Ori Biotech’s Game-Changing CollaborationIn the fast-paced world of biotechnological innovation, where the stakes are as high as the potential benefits, the partnership betw...

MaxCyte Expands Horizons with SeQure Dx Acquisition Amidst Financial ChallengesIn a noteworthy development within the biotech sector, MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a prominent player in cell-engineering solut...

MaxCyte Inc.: A Legacy of Cell Engineering with Financial Challenges AheadMaxCyte, a prominent player in the biopharmaceutical landscape and a pioneer in cell engineering, recently released its preliminary unaudited fin...

IntroductionMaxCyte Inc. proudly commemorates 25 years of innovation in the field of cell engineering, a milestone marked by numerous advancements in cell and gene therapy since its inception in 1999. Despite its celebr...

In an ambitious stride toward transforming the landscape of genetic disease treatment, MaxCyte Inc. a global leader in cell engineering and therapeutic research, has entered into a strategic platform license agreement w...

In a series of transformative agreements, MaxCyte, a pioneering force in cell engineering and electroporation technology, has inked strategic platform licenses with three distinguished biotech companies: Legend Biotech,...

MaxCyte Partners with Be Biopharma to Advance Engineered B Cell MedicinesMaxCyte, a leading biotechnology company, has recently announced a strategic platform license agreement with Be Biopharma, a pioneering player in...

MaxCyte and Wugen Partner to Accelerate Manufacturing of Cell Therapies for Cancer TreatmentMaxCyte Inc. and Wugen Inc. have recently announced a strategic platform license agreement aimed at expediting the scale-up of...

In a groundbreaking move set to transform the landscape of cancer immunotherapy, MaxCyte, a leading cell-based medicines and life sciences company, has recently signed a strategic platform license agreement with Imugene...

MaxCyte Inc., a leading global company specialized in scalable high-performance cell engineering, and Lion TCR, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR) T cell therapies...

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023MaxCyte Inc, a leading cell engineering company, recently announced a significant change in its management as Doug Doerfler, the current President an...